


A new therapeutic strategy to improve treatment of aggressive endometrial cancer

November 2 2022



ERK5 inhibition impairs EC cell proliferation. **A** Genomic profiles of components of the MEK5-ERK5 pathway in EC patients obtained from Uterine Corpus Endometrial Carcinoma data set (TCGA, PanCancer Atlas). Data set from cBioportal. *MAPK7*, ERK5 gene; *MAP2K5*, MEK5. **B** Kaplan–Meier plots overall survival (left) and progression-free (right) in uterine corpus endometrial carcinoma patients with high (red), quartile 1) or normal (blue, quartile 2–3) ERK5 mRNA levels (data set from cBioportal). P values were obtained using log-rank test. **C** Chemical structure of JWG-071. **D** Immunoblot analysis of the

effect of JWG-071 on EGF stimulation. **E** MTT cytotoxicity (48 h) assay in a panel of human EC cells. **F** 14-day clonogenic assay. **G** Effect of ERK5 silencing on the proliferation of EC cell. ERK5 silencing was carried out with two different specific siRNA sequences. Scr., scramble siRNA. Cell proliferation was measured at three days of culture using crystal violet assays. ^{***}, *P*

Citation: A new therapeutic strategy to improve treatment of aggressive endometrial cancer (2022, November 2) retrieved 25 April 2024 from <https://medicalxpress.com/news/2022-11-therapeutic-strategy-treatment-aggressive-endometrial.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.